Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H20N4O |
| Molecular Weight | 320.3883 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CN2CCC1[C@H](C2)OC3=NN=C(C=C3)C4=CC5=C(NC=C5)C=C4
InChI
InChIKey=LUKNJAQKVPBDSC-SFHVURJKSA-N
InChI=1S/C19H20N4O/c1-2-16-15(5-8-20-16)11-14(1)17-3-4-19(22-21-17)24-18-12-23-9-6-13(18)7-10-23/h1-5,8,11,13,18,20H,6-7,9-10,12H2/t18-/m0/s1
| Molecular Formula | C19H20N4O |
| Molecular Weight | 320.3883 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. | 2010-09-01 |
|
| In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. | 2010-09-01 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:29:50 GMT 2025
by
admin
on
Mon Mar 31 18:29:50 GMT 2025
|
| Record UNII |
SXS38HR98H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11151363
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
PRIMARY | |||
|
SXS38HR98H
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
PRIMARY | |||
|
855291-54-2
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: NeuroSearch; Developer: Abbott Laboratories; Mechanism of Action: Nicotinic receptor modulator; Highest Development Phase: Discontinued for CNS disorders, Cognition disorders; Most Recent Events: 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie, 31 Mar 2009 Discontinued - Phase-I for Cognition disorders in USA (unspecified route), 31 Mar 2009 Discontinued - Phase-I for CNS disorders in USA (unspecified route)
|
